Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Volrustomig
Other

Volrustomig

Tracked across 1 events · 20 articles · First seen Aug 17, 2026 · Last active Aug 17, 2026

Sentiment
-30
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 -30
Business
AstraZeneca discontinues volrustomig lung cancer trial
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: Volrustomig is the experimental drug whose Phase III trial was discontinued due to lack of efficacy. This reduces its commercial potential, though other trials in different cancer types continue.
Aug 17, 2026 · 20 articles
ERGEN INTELLIGENCE
Track Volrustomig live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.